Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19
AUTHORS: Pierre Kory, MD1*, G. Umberto Meduri, MD2†, Jose Iglesias, DO3, Joseph Varon, MD4 , Keith Berkowitz, MD5 , Howard Kornfeld, MD6 , Eivind Vinjevoll, MD7 , Scott Mitchell, MBChB8 , Fred Wagshul, MD9, Paul E. Marik, MD10
Corresponding Author: Pierre Kory, MD, MPA – pkory@flccc.net
Abstract
In March 2020, the Front Line COVID-19 Critical Care Alliance (FLCCC) was created and led by Professor Paul E. Marik to continuously review the rapidly emerging basic science, translational, and clinical data to develop a treatment protocol for COVID-19. The FLCCC recently discovered that ivermectin, an anti-parasitic medicine, has highly potent anti-viral and anti-inflammatory properties against SARS-CoV-2 and COVID-19. This conclusion is based on the increasing study results reporting effectiveness, not only within in-vitro and animal models, but in numerous clinical trials




